CD38 Targeting in Aggressive, Treatment-Refractory Cutaneous T-Cell Lymphomas

Article Hematology

Primary cutaneous lymphoma: recommendations for clinical trial design and staging update from the ISCL, USCLC, and EORTC

Elise A. Olsen et al.

Summary: The number of patients with primary cutaneous lymphoma (PCL) is small compared to other non-Hodgkin lymphomas (NHLs), and there are many subtypes. Clinical trial guidelines for PCL, except for mycosis fungoides/Sezary syndrome, are lacking. To address this gap, international dermatology organizations propose updated staging and guidelines aligned with the Lugano guidelines, aiming to facilitate regulatory approval, encourage cooperative trials, and assess comparative efficacy of therapeutic agents.

BLOOD (2022)

Add to Collection

Article Biotechnology & Applied Microbiology

CD38 Expression by Circulating and Skin-Infiltrating Lymphocytes from Sezary Syndrome Patients: A Flow Cytometry and Immunohistochemistry Study

Pietro Quaglino et al.

Summary: This study analyzed the expression of CD38 in SS patients and found that the majority of patients had a CD38-negative phenotype in both skin and blood. However, a small subgroup of patients expressed CD38 in either the skin or blood, which may have implications for immune defense regulation and antibody therapy.

DISEASE MARKERS (2022)

Add to Collection

Meeting Abstract Hematology